The Role of Biopharmaceutics in Early Drug Development

Chris joined Quotient Sciences in 2015 as a Research Fellow, bringing over 20 years’ experience across pharmaceutical sciences and biopharmaceutics through a series of previous technical and leadership roles at Sanofi, Pfizer, AstraZeneca and Walgreens Boots Alliance. His expertise ranges from early pre‑formulation and biopharmaceutical assessments ensuring appropriate new chemical entity selection, through development of a wide range of dosage forms including preclinical and early clinical inhalation, topical, oral immediate release and modified release formulations, to maintenance and life-cycle management of existing marketed products. Chris’ role at Quotient involves designing science­-­led, robust, clinical study programs which maximise output for clients, in addition to providing scientific support throughout study delivery. Chris holds a Bachelor of Science degree in Medicinal Chemistry from Newcastle University and Postgraduate Certificate in Education from Nottingham Trent University.

Shriram is a member of the scientific consulting group at Quotient and has a comprehensive experience in the biopharmaceutical aspects of formulation design and development. He has a thorough understanding of the new technologies in the field of drug absorption modelling and has been involved in the development and optimization of biorelevant tests to provide in vitro, in silico and in vivo correlations. Prior to joining Quotient in 2019, Shriram was a member of the modelling and simulations group at Certara, UK, where he was involved in the development of mechanistic modelling tools to inform a rational formulation design.